All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine.

ABSTRACT:

Background

Insulin therapy in type 2 diabetes may increase mortality and cancer incidence, but the impact of different types of basal insulins on these endpoints is unclear. Compared to the traditional NPH insulin, the newer, longer-acting insulin analogues detemir and glargine have shown benefits in randomized controlled trials. Whether these advantages translate into lower mortality among users in real life is unknown.

Objective

To estimate the differences in all-cause and cause-specific mortality rates between new users of basal insulins in a population-based study in Finland.

Methods

23 751 individuals aged ≥40 with type 2 diabetes, who initiated basal insulin therapy in 2006-2009 were identified from national registers, with comprehensive data for mortality, caus

SUBMITTER: Strandberg AY 

PROVIDER: S-EPMC4816506 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature